We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMAMP
RNS Number : 5404L
Amphion Innovations PLC
20 April 2018
Amphion Innovations plc
("Amphion" or "the Company")
Directorate Change
London and New York, 20 April 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that Miroslaw Izienicki and Richard Mansell-Jones have resigned as Non-executive Director and Chairman respectively and will leave the Board with immediate effect.
The Company has begun the process of seeking suitable candidates to fill these positions and will update shareholders accordingly.
Richard C.E. Morgan, Chief Executive Officer of Amphion said: "I would like to thank Miroslaw and Richard for their service to Amphion over the years. We wish them both well for the future.
"Our team at Amphion remains confident in the futures of Motif Bio and Polarean Imaging, both now publically listed companies, as well as the future potential of FireStar Software. We believe that as our companies' progress, Amphion's shareholders will benefit in turn and we look forward to building on that base with new investment opportunities in the life-sciences sector."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224 Charlie Morgan Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20 and Corporate Broker) 7886 2500 Freddy Crossley / Ryan McCarthy / Emma Earl (Corporate Finance) Charlie Leigh-Pemberton (Corporate Broking) Northland Capital Partners Limited (Joint Tel: +44 (0)20 3861 Corporate Broker) 6625 David Hignell (Corporate Finance) John Howes (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or Anna Dunphy / Paul McManus amphion@walbrookpr.com
About Amphion Innovations plc - www.amphionplc.com
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFMGMDMLGGRZZ
(END) Dow Jones Newswires
April 20, 2018 02:00 ET (06:00 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
